Tumor Models

WuXi Biology has a significant experience in oncology drug discovery. We offer a large collection and tumors model for small & large molecule drug discovery.

  • A large collection of cell line-derived xenograft (CDX) tumor models with an imaging based orthotopic/metastatic CDX platform covering 16 tumor types
  • Patient-derived xenograft (PDX) tumor models covering 20 cancer types, drug resistant model and mouse clinical trial enabling translational research
  • Syngeneic tumor models covering 20 cancer types, enabled with immunotherapy SOC, TIL analysis and RNAseq profiling.
  • Human immune checkpoint gene KI mouse models
  • hPBMC/HSC humanized models
  • Extensive panel of c-MET related CDX and PDX tumor models

Cell line-derived xenograft (CDX) tumor models

  • 320+ validated models covering 30 tumor types
  • 77+ cell lines derived from PDX models
  • Available data of sensitivities to SOC (standard of care)
  • Imaging-based orthotopic/metastatic tumor models
  • Brain/bone metastatic models of lung/breast cancer cell lines
CDX tumor models
*validated with SOC compound
CDX, tumor models
*validated with SOC compound

41 Luciferase Labelled Orthotopic/Metastatic Tumor Models

  • Covering 17 tumor types
  • Bioluminescent imaging system in SPF barrier
tumor models, orthotopic models, luciferase, tumor types
O: orthotopic model;  M: metastatic model;  S: validated with SOC; IC: intracranial model; Syngeneic models marked in red

Patient-derived xenograft (PDX) tumor models

PDX, patient-derived xenograft tumor models and drug-resistant models covering multiple cancer types

A Comprehensive PDX Collection of Asia Prevalent Tumors with Genomic Profiling

PDX, tumor models
Profiled number marked in red

Syngeneic tumor models

  • 87 Syngeneic models (mouse, rat, hamster) covering 20 cancer types
  • Comprehensive panel of orthotopic syngeneic tumor models
  • Responsiveness to immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4, etc.)
  • Tumor-infiltrating leukocytes (TILs) map
  • WES, RNA-seq and scRNA-seq characterization

syngeneic, tumor models, checkpoint, TILs, RNA-seq, scRNA-seq
Orthotopic/metastasis models marked in red; models with reference drug treatment data marked as S; models with genomic profiling data marked GC (cell-line profiled), GT (tumor tissue profiled), or GC/T (both)

Genetically engineered models

  • 48 engineered cell lines based on construct overexpression or gene knock-in
  • Pharmacologically validated both in vitro and in vivo
  • Focusing on drug-resistant mutation introduction and IO-related checkpoint humanization
  • Example targets: EGFR, ROS1, ALK, RET, FLT3, BTK, Claudin18.2, PD-L1

hPBMC/HSC Humanized Models

hPBMC Humanized Models

  • Established models for immune-checkpoint inhibitor and bi-specific antibody candidates in a human-resembling immune system.
  • Annotation for both immune cells (phenotyping, biomarker, functions) and tumor cells (expression, mutation)
  • Different PBMC delivery systems (systemic injection or co-inoculation with tumor)

HSC Humanized Models

  • Available humanized models from CIEA, combined with WuXi PDX/CDX models.
  • Customizable with human cytokine transgenic mice (GM-CSF/hIL-3 or hIL-2) to improve the reconstitution of myeloid lineage.

Established CDX/PDX-hPBMC Models

hPBMC, tumor models
*Target efficacy validation

Human immune checkpoint gene KI mouse models

KI (Knock-in) mice offer the possibility to study clinical grade checkpoint antibodies targeting human checkpoints in the context of a fully functional immune system. WuXi Biology offers efficacy studies in different mouse strains with human targets KI in mice and cell line, and comprehensive flow cytometry to evaluate target expression and immune function.

  • Collection of various targets and background mouse strains
  • Validated with launched or most advanced clinical grade checkpoint antibodies
  • Double checkpoint KI mice customizable for combination (PD1 + OX40, PD1 + TIM3)
human immune checkpoint gene KI knock-in mouse models to study checkpoint antibodies

Immuno-avatar humanized models

  • Mouse models harboring human tumor and human immune ceils
  • Three different diagram of hPBMC humanization for mature T cell engraftment
  • HSC (CD34+) avatar and next generation immune avatar for multiple-lineage engraftment (Myeloid, NK, DC)
  • IO-CDX and IO-PDX models with cancer targets and HLA information

Related Resources View All

Metastasis-Related In Vitro Assays and Xenograft Models

Resource Type: Latest Science Presentation

Oncolytic Virus Platform

Resource Type: Latest Science Presentation

Evaluation Platform for Bispecific Antibodies

Resource Type: Latest Science Presentation

Enzalutamide-resistant LNCaP ARF877L Mutation KI model

Resource Type: Latest Science Presentation

Tumor Cell Panel | Screening Services

Resource Type: Brochure

Orthotopic and Metastasis Syngeneic Models

Resource Type: Latest Science Presentation

DLL3-Related PDX Models

Resource Type: Latest Science Presentation

c-MET Related In Vivo Models

Resource Type: Latest Science Presentation

BRAF-Related In Vivo Models

Resource Type: Latest Science Presentation

Xenograft and Syngeneic Tumor Models in Rats

Resource Type: Latest Science Presentation

KRAS-related Genetically Engineered Cell Lines and In Vivo Models

Resource Type: Latest Science Presentation

CDK4/6 Inhibitor Resistant Breast Cancer Models

Resource Type: Latest Science Presentation

WuXi AppTec Discovery Services

Resource Type: Brochure

Translational Oncology

Resource Type: Brochure

Immuno-Oncology Services

Resource Type: Brochure

Hepatocellular Carcinoma (HCC) Models

Resource Type: Brochure